Papers

10

Total Citations

105

H-Index

5

About

Antonio Cicione is a urologic surgeon and researcher whose work centers on improving surgical outcomes and patient quality of life in prostate and kidney cancer care. He has made significant contributions to active surveillance protocols, demonstrating that biomarkers PHI and PCA3 enhance the prognostic performance of PRIAS and Epstein criteria for identifying insignificant prostate cancer—a study cited 50 times. Cicione has pioneered minimally invasive techniques, notably developing the purely off-clamp sutureless robotic partial nephrectomy, which preserves renal function without ischemia; his initial experience and multi-institutional analyses (8 and 3 citations) show this approach is safe even for novice robotic surgeons. He has also benchmarked the learning curve for robotic radical cystectomy with intracorporeal neobladder using CUSUM analysis (14 citations), advancing complex surgical training. His prospective multicenter work correlating spared urethral length with early continence recovery after robotic prostatectomy (6 citations) directly addresses a key patient concern. With over 100 cumulative citations, Cicione’s research blends technical innovation with rigorous outcomes assessment, offering practical insights for surgeons adopting advanced robotic techniques.

Research Focus

Key Achievements

5
H-Index
10
Papers
105
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance
50 citations · 2015
📈 Most Prolific Year: 2024 (4 Papers)
🤝 Key Collaborators: 90
🏛 Institutions: Magna Graecia University, Azienda Ospedaliera Sant'Andrea, Sapienza University of Rome, CTO Andrea Alesini

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago